Now with Spectral Shift and TRIC, two methods for measuring molecular interactions, Dianthus delivers high-quality data, has the sensitivity to detect more true binders, and requires less assay development to give you results from real-life samples. Immobilization-dependent SPR, and sample-consuming ITC really struggle with affinity screening campaigns for applications involving PROTAC binary and ternary complexes, fragment libraries, and intrinsically disordered proteins. These are precisely the applications where Dianthus excels.
Ready to tackle your challenging affinity screening?
Discover tools you can use
See more related content

NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....

Watch this webinar if you’re working in the field of small molecule drug discovery and want to learn how scientists in this field use biophysical tools to search for the most promising lead compounds.

With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...

Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...



With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...

Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat



Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com

Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target

There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...

Most labs dedicated to drug discovery — in big pharma, biopharma, or CROs — make it a priority to have an adequate lineup of instruments for their screening campaigns. They decide on what...